Key result
Heparin prevents acute thrombosis during PCI with cost and reversibility advantages over bivalirudin.
Why the study?
Optimal heparin dosing regimens and their efficacy compared with other anticoagulants such as bivalirudin in PCI remain debated.
Population
Patients undergoing percutaneous coronary intervention
Comparison
Heparin monotherapy and with glycoprotein IIb/IIIa inhibitors vs bivalirudin and other anticoagulants
Design
Review
Authors
Loading...
Heparin's reversibility and cost sustain its PCI role; review leaves optimal dosing and bivalirudin comparisons open for prospective trials.
This review highlights the ongoing debate regarding optimal heparin dosing and its comparative efficacy against bivalirudin in minimizing thrombotic and bleeding risks during PCI.
Lee et al. (2015) conducted a review in Percutaneous coronary intervention (PCI). Heparin vs. Bivalirudin was evaluated. Heparin plays a critical role in preventing acute thrombotic events during percutaneous coronary intervention, offering advantages in reversibility and cost compared to bivalirudin, though optimal dosing regimens remain debated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: